Trial Profile
Safety, efficacy and pharmacokinetics of Carfilzomib in combination with lenalidomide and dexamethasone (CRd regimen) in Japanese subjects with relapsed/refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2016
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Ono Pharmaceutical
- 31 Aug 2016 New trial record